abstract |
The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immuno-genic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, includ-ing Staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal MSCRAMM or MSCRAMM-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy. |